MedTrace Logo

68Ga Citrate PET/MRI for Evaluation of Fever of Unknown Origin (FUO)

NCT04139395 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2022-08-22

No results posted yet for this study

Summary

This is a Phase III study to evaluate 68Ga Citrate PET/MRI for detection of origin of fever of unknown origin.

Conditions

  • Fever of Unknown Origin

Interventions

DRUG

68Ga-Citrate PET/MRI

Participants will be injected intravenously (IV) with 370 MBq of 68Ga Citrate. 45 -60 minutes after the radiopharmaceutical IV administration, whole body data acquisition at the PET/MRI suite will begin.

DRUG

67Ga-Citrate SPECT

67Ga-Citrate will be used as the radiotracer for a regular medical care SPECT scan

DEVICE

Positron Emission Tomography

Imaging with 68Ga-Citrate PET/MRI

DEVICE

Magnetic Resonance Imaging

Imaging with 68Ga-Citrate PET/MRI

DEVICE

SPECT

Imaging with 67Ga-Citrate radiotracer. SPECT scan will be conducted as part of regular medical care.

Sponsors & Collaborators

  • Carina Mari Aparici

    lead OTHER

Principal Investigators

  • Carina Mari Aparici, MD · clinical professor

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-15
Primary Completion
2020-12-20
Completion
2021-12-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04139395 on ClinicalTrials.gov